Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can On-and-Off phentermine melt deep belly fat?

NCT ID NCT07870668

Disease control Sponsor: OSCAR MANUEL TORRES FALCON Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 13, 2026 · Last updated Oct 14, 2026 · Updated 1 time

Summary

Researchers are testing whether intermittent phentermine, taken in three-month cycles with one-month breaks, helps adults with overweight or obesity lose body fat and visceral fat. The trial enrolls 600 adults aged 21 to 40 with a BMI of 27 to 35. Participants receive lifestyle counseling alone or lifestyle counseling plus phentermine at 15 mg, 30 mg, or 37.5 mg daily. The study measures changes in total body fat, visceral fat, waist circumference, and lean mass over 14 months, along with heart rate, blood pressure, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
phentermine, an appetite-suppressing weight-loss drug
What this could lead to
If intermittent phentermine works, it could offer a way to reduce body fat and visceral fat with planned breaks from the drug, which may limit side effects and improve tolerability.
What could go wrong
Phentermine is a stimulant that can raise heart rate and blood pressure, and the trial excludes people with uncontrolled hypertension or significant heart disease. Intermittent dosing may not produce lasting fat loss, and participants may regain weight during the months off the drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

600 people

The number who actually took part.

Started

Mar 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 21 to 40 years. * Body mass index (BMI) 27 to 35 kg/m². * Eligible for structured obesity treatment. * Willingness to complete serial body-composition assessments. Exclusion Criteria: * Pregnancy or breastfeeding. * Known contraindication to sympathomimetic therapy. * Uncontrolled hypertension. * Clinically significant cardiovascular disease. * Medical or psychiatric conditions judged to make participation unsafe or compromise protocol adherence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

Contacts and locations

Locations

  • Hospital Medica Campestre

    León, Guanajuato, 37180, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.